DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

Upgrades Summary - Morgan Stanley upgraded Lemonade (LMND) to Overweight from Equal Weight with a price target of $85, increased from $80, citing the partnership with Tesla (TSLA) as a significant first step that provides Lemonade with a first-mover advantage in data analysis and practical experience [2] - Barclays upgraded Align Technology (ALGN) to Overweight from Equal Weight with an unchanged price target of $200, noting that the stock's risk/reward profile has improved due to a 15% pullback driven by the Middle East conflict from its February high [2] - Wells Fargo upgraded Dover (DOV) to Overweight from Equal Weight with a price target of $230, up from $210, indicating that U.S. macro data supports a short-cycle recovery [2] - Stifel upgraded Ichor Holdings (ICHR) to Buy from Hold with a price target of $55, increased from $30, expressing renewed confidence that the company's gross margin trajectory is entering an up-cycle sweet spot [2] - Piper Sandler upgraded Tandem Diabetes (TNDM) to Overweight from Neutral with a price target of $33, raised from $21, following an analysis of Tandem's pharmacy pricing benefits and international direct market opportunities [2]